Jacobson Mark L. 4
4 · Axsome Therapeutics, Inc. · Filed May 28, 2025
Insider Transaction Report
Form 4
Jacobson Mark L.
Chief Operating Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2025-05-27−20,673→ 0 totalExercise: $6.47From: 2016-09-15Exp: 2025-09-15→ Common Stock (20,673 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-05-28−20,000→ 0 totalExercise: $6.47From: 2016-09-15Exp: 2025-09-15→ Common Stock (20,000 underlying) - Sale
Common Stock
2025-05-27$104.66/sh−20,673$2,163,636→ 5,783 total - Sale
Common Stock
2025-05-28$103.45/sh−20,000$2,069,000→ 5,783 total - Exercise/Conversion
Common Stock
2025-05-27$6.47/sh+20,673$133,754→ 26,456 total - Exercise/Conversion
Common Stock
2025-05-28$6.47/sh+20,000$129,400→ 25,783 total
Footnotes (5)
- [F1]Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within 12 months.
- [F2]Such transaction was pursuant to a pre-approved 10b5-1 plan.
- [F3]Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
- [F4]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $103.96 and $106.44.
- [F5]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $102.67 and $104.22.